Retension Pharmaceuticals Inc.: Oppenheimer initiates coverage with outperform rating; price target $50
RTSN•Oppenheimer initiated coverage of Retension Pharmaceuticals with an outperform rating and a $50 price target.
Related News
BMO partners with Redion to expand travel insurance offering
BMO•
Nexera subsidiary Fort Technology wins approval for TSX Venture delisting
FRTT•
Revvity rises on annual profit forecast raise, Q3 results beat
RVTY•
Shopify Q3 revenue rises 32%, GMV hits $119 bln
SHOP•
Match Group: Truist Securities raises target price to $44 from $41
MTCH•